electroCore Third Quarter 2026 Earnings Call - ELECTROCORE INC

Financial Performance:

• Net sales for Q3 2026 reached a record $9.7 million, representing a 12% year-over-year increase, driven primarily by Quell Fibromyalgia and Prescription GammaCore.
• Gross margin expanded to 88.5% (from 86.0% in Q3 2025) due to favorable product mix.
• Operating loss narrowed to $1.6 million; GAAP net loss was $1.3 million ($0.13/share), an improvement of $1.3 million or $0.20/share from the prior year period.
• Adjusted EBITDA loss improved significantly to a record low of $700,000, a $1.4 million (67%) year-over-year improvement, ahead of expectations.
• Cash and marketable securities stood at $7.5 million as of September 30, 2026; inventory increased to $4 million to support supply for forecasted growth.
• Operating expenses were $10.1 million, largely flat year-over-year despite a $300,000 increase in sales and marketing, offset by a $200,000 decrease in general and administrative expenses.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance revised to $39–$42 million (previously >30% growth target), shifting expected acceleration to 2027 due to sales organization ramp-up timing.
• Provided preliminary 2027 growth guidance of 30–40% year-over-year.
• Targeting the first quarter of positive adjusted EBITDA by the end of 2027, contingent on revenue growth and operating leverage without needing new dilutive equity financing.
• CIPN 510K clearance expected in the second half of H1 2027; potential revenue impact from CIPN indication considered "gravy" or upside to the 2027 base case, not the primary driver of current guidance.

Business Segments and Product Lines:

• Quell Fibromyalgia: Surpassed 1,000 VA patients prescribed in 2026; October was the strongest month on record with revenue and new patient orders exceeding January and February combined.
• GammaCore: Continued strong utilization in VA; new independent representatives are averaging $210,000/month in VA revenue (up 30% from previous territory performance) and trending toward $300,000/month.
• TrueVega (DTC): Revenue intentionally reduced to avoid "empty calorie" spending amidst rising ad costs; Return on Ad Spend (ROAS) improved 8% YoY. Future DTC growth is expected but will be slower and more profitable.
• CIPN Opportunity: Filed 510K pre-market notification for Quell for chemotherapy-induced peripheral neuropathy; FDA review underway with breakthrough designation already secured.
• Strategic Partnership: Lovell Government Services now handles 91% of VA orders (up from 57% in June), reducing transaction fees by 3% and freeing internal resources for market expansion.

Market and Competitive Landscape:

• VA Market Penetration: Expanded to 7 new VA accounts in Q3; top 15 accounts' revenue concentration decreased to 51%, and no single facility accounted for >10% of VA sales.
• Refill Metrics: National refill rate currently at 42% YTD with a goal to reach 70%; new patient orders (NPOs) from the VA grew 21% YoY.
• Commercial Expansion: Engaging Kaiser (outside California), DoD/TRICARE, and pilots for federal workers' compensation; established relationships with VA Women's Health and First Responders consultants.
• Addressable Market: CIPN estimated at $600–$700 million total US market and $15–$20 million within the VA; identified as a "blue ocean" with no current device/pharma alternatives.
• New Frontiers: Exploring applications for high-stress roles (Air Force, Air Traffic Controllers, Police/SWAT) based on emerging clinical data regarding physical and mental performance.

Risks and Challenges:

• Regulatory Timelines: FDA approval for CIPN 510K is subject to standard review cycles and potential Q&A delays; 2027 CIPN revenue is not guaranteed in the base guidance.
• DTC Profitability: Rising competition increased branded search cost-per-click by 42% and competitor bidding by 60%, necessitating reduced spend to maintain margins.
• Over-the-Counter (OTC) Delay: Quell OTC launch delayed pending resolution of a 2017 Form 483 specific to the former Neurometrics OTC product.
• Execution Risk: Reliance on rapid ramp-up of new sales talent and territory restructuring to achieve 2027 growth targets.

Management Commentary and Tone:

• Tone was confident and disciplined, emphasizing a strategic shift from top-line chasing to profitable growth and operational efficiency.
• Leadership highlighted a "foundation-building" quarter with record sales and the lowest operating loss in history.
• Management expressed strong conviction in the 2027 inflection point, citing early KPIs from the new sales force that validate the strategic pivot.
• Emphasis placed on "accountability" and "coverage" as the pillars for future growth, with a deliberate move away from short-term financial engineering.

Analyst Questions and Answers:

• Sales Force Capacity: New reps are targeting 14 patients/month per account (split between migraine and fibromyalgia); market saturation is deemed low due to uncared-for patients in community care.
• CIPN Commercial Strategy: Plans to leverage the existing sales force with potential for a more specialized oncology focus at launch.
• Guidance Confidence: 2027 growth confidence stems from fully staffed VA accounts, higher productivity of new hires, and data-driven refill management.
• CIPN Market Size: Addressable market estimated at $600–$700M (US) and $15–$20M (VA); expansion outside federal channels expected once reimbursement is established.
• FDA Timeline: Expected 90-day review clock; best-case FDA response anticipated in H2 of Q1 2027; 2017 Form 483 not expected to impact current timeline.
• DTC Strategy: Confirmed intention to reduce DTC volume to improve margins, accepting lower headline revenue in exchange for higher contribution margin per dollar.

Other Key Points:

• Sales Force Restructuring: Split VP Sales role into East/West Area VPs; added two Regional Directors; new hires are onboarding 3x faster (2 months vs. 6–7 months previously) with higher early productivity.
• Refill Improvement Initiatives: Piloting new patient training to improve compliance and refill rates, aiming to bridge the gap from current 42% to 70%.
• Capital Management: Evaluating refinancing of existing term loans to extend principal repayment timing, potentially extending the cash runway to support the 2027 profitability path.
• Productivity Metrics: New patient starts for new representatives reached 3.4 per account by month three, compared to 0.3 for previous hires.